Journal of AIDS & Clinical Research

Jonathan D Fuchs

Publications

• Research Article
  Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals
  Author(s): Jonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, Cecilia Morgan, Peter B Gilbert, Nidhi Kochar, Stephen C DeRosa, Georgia D Tomaras, Theresa M Wagner, Lindsey R Baden, Beryl A Koblin, Nadine G Rouphael, Spyros A Kalams, Michael C Keefer, Paul A Goepfert, Magdalena E Sobieszczyk, Kenneth H Mayer, Edith Swann, Hua-Xin Liao, Barton F Haynes, Barney S Graham, M Juliana McElrath and for the NIAID HIV Vaccine Trials NetworkJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, Cecilia Morgan, Peter B Gilbert, Nidhi Kochar, Stephen C DeRosa, Georgia D Tomaras, Theresa M Wagner, Lindsey R Baden, Beryl A Koblin, Nadine G Rouphael, Spyros A Kalams, Michael C Keefer, Paul A Goepfert, Magdalena E Sobieszczyk, Kenneth H Mayer, Edith Swann, Hua-Xin Liao, Barton F Haynes, Barney S Graham, M Juliana McElrath and for the NIAID HIV Vaccine Trials Network
  
  Background: Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may circumvent these issues, but there are few data on the safety and immunogenicity of rAd35 directly compared to rAd5 following human vaccination. Methods: HVTN 077 randomized 192 healthy, HIV-uninfected participants into one of four HIV-1 vaccine/placebo groups: rAd35/rAd5, DNA/rAd5, and DNA/rAd35 in Ad5-seronegative persons; and DNA/rAd35 in Ad5-seropositive persons. All vaccines encoded the HIV-1 EnvA antigen. Antibody and T-cell responses were measured 4 weeks post boost immunization. Results: All vaccines were generally well tolerated and similarly immunogenic. As compared to.. Read More»
  DOI: 10.4172/2155-6113.1000461

  Abstract PDF